BofA analyst Tazeen Ahmad lowered the firm’s price target on Argenx to $577 from $604 but keeps a Buy rating on the shares. The analyst cites the company having reported that its phase 3 ADVANCE-SC trial evaluating SC efgartigimod in ITP failed to meet the primary endpoint. The firm notes however that the company commented they are still expecting a regulatory decision in Japan for the IV formulation in Q1 of next year and have plans to explore additional submissions in other regions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx selloff on failed study a buying opportunity, says Wells Fargo
- Argenx announces ADVANCE-SC study did mot meet primary, secondary endpoints
- argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
- argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
- Argenx announces EC approval of subcutaneous VYVGART for gMG
